STERIS plc Stock News

Pune, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Global Surgical Display Market report delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. Surgical Display market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue. According to a study by Researcher, is anticipated to reach at USD 655.1 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 0.9% from 2021 to 2028. Get a Sample Copy of the Report at - https://www.absolutereports.com/enquiry/request-sample/20198842 The top players are concentrating mostly on technical developments in order to increase efficiency. The long-term growth patterns for this market can be taken by continuing the current development progresses and financial strength to participate in the best strategies.

The Rising Profits Estimates screen reveals hot stocks to watch, such as Costamare, Ares Management and Steris.

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

Steris plc (NYSE: STE ) reported Q3 FY22 sales of $1.2 billion , +49% Y/Y, in line with the consensus of $1.2 billion. Constant currency organic revenue increased 9%. Adjusted EPS of $2.12, compared with the previous year''s third quarter of $1.73, beating the consensus of $1.97. Healthcare segment revenue grew 46% to $759.7 million, with $210.3 million added from acquisitions, reflecting an 84% increase in consumable revenue, … Full story available on Benzinga.com

STERIS plc. (STE) CEO Dan Carestio on Q3 2022 Results - Earnings Call Transcript

Despite a bottom line beat in its fiscal Q3 2022 results, shares of Steris are unchanged in after-hours trading.

Steris press release (STE): Q3 Non-GAAP EPS of $2.12 beats by $0.16.Revenue of $1.2B (+48.3% Y/Y) in-line.FY22 Guidance:The Company is updating its expectations for fiscal 2022

DUBLIN, IRELAND, Feb. 08, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 third quarter ended December 31, 2021. Revenue as reported for the quarter increased 49% to $1.2 billion compared with $808.9 million in the third quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 9% for the third quarter of fiscal 2022 as compared to the third quarter of fiscal 2021.

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships Dr. Gregory Berk joins with 30+ years of medical experience with oncology expertise in clinical trials, drug development, and regulatory strategy in both industry and academia GARDEN CITY, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR ), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointments of Mr. David Dvorak and Dr. Gregory Berk to Beyond Cancer''s Board of Directors. Following these appointments, the Beyond Cancer Board of Directors will be comprised of six members with no further additions planned.

There are medical emergency times when both a National Emergency and a Personal Emergency must have attention. People skills, facilities, time will be shared to preserve life. Easiest to picture is a

Steris (NYSE:STE) declares $0.43/share quarterly dividend, in line with previous.Forward yield 0.77%Payable March 24; for shareholders of record Feb. 25; ex-div Feb.

DUBLIN, IRELAND, Jan. 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 third quart